Iressa

(Gefitinib)

ApprovedSmall molecule

Gefitinib is used to treat certain types of lung cancer, particularly in patients whose cancer cells have specific genetic mutations. It works by blocking a protein that helps cancer cells grow.[2] Iressa is currently approved and in use across 56 indications[4].[1]

Iressa is one of 1033 small molecule programs targeting Glioma. It is currently in Approved.

Indications

251

Total Trials

Active Trials

1,032

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Pancreatic CarcinomaActive, not recruiting

Head and Neck CarcinomaActive, not recruiting

Bone MetastasisActive, not recruiting

Colorectal CarcinomaActive, not recruiting

Gallbladder CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaApproved

Salivary Gland CancerActive, not recruiting

Kidney CancerActive, not recruiting

Lung CancerApproved

GliomaPhase 1

Active, not recruiting

Pancreatic CarcinomaPhase 2

Active, not recruiting

Head and Neck CarcinomaPhase 2

Active, not recruiting

Bone MetastasisPreclinical

Active, not recruiting

Colorectal CarcinomaPhase 2/Phase 3

Active, not recruiting

Gallbladder CarcinomaPhase 2

Active, not recruiting

Nasopharyngeal CarcinomaApproved

Approved

Salivary Gland CancerPhase 2

Active, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Lung CancerApproved

Approved

Showing 10 of 56 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Iressa

AstraZeneca

Approved

15 2

Avastin

BBio-Thera Solutions

Preclinical

153 3

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 4

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 5

Chirocaine

PPurdue Pharma LP

Preclinical

1 6

Vfend

PPrism Pharmaceuticals

Preclinical

—7

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 8

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 9

Tianeptine

Pfizer

Preclinical

1 10

Escitalopram Oxalate

TTorrent Pharmaceuticals Limited

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Locally Advanced or Metastatic NSCLC

NCT04143607

Q4 2026

Phase 1Active, not recruiting

NSCLC

NCT03333343

Phase 3Active, not recruiting

Metastatic NSCLC

NCT02411448

Q3 2027

Phase 2Active, not recruiting

Treatment

NCT03040973

Q4 2027

Phase 1/2Active, not recruiting

Lung Cancer

NCT03122717

Phase 2Active, not recruiting

Osimertinib

NCT02856893

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer37 trials

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Completed·HHutchison Medipharma Limited·Phase 2·NCT02976116·50 enrolled

Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT01749072·120 enrolled

Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer

Unknown status·SSun Yat-sen University·Phase 3·NCT01951469·160 enrolled

Show 34 more trials

A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR

Completed·NNational Cancer Centre, Singapore·Phase 1·NCT01570296·38 enrolled

Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)

Completed·—·Phase 2·NCT00824746·23 enrolled

Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)

Completed·NNational Cancer Center, Korea·Phase 2·NCT00452244·110 enrolled

Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00091156·598 enrolled

Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00096486·74 enrolled

Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Completed·WWake Forest University Health Sciences·Phase 1·NCT00310154·45 enrolled

Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00049543·503 enrolled

Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Unknown status·—·Phase 2·NCT01024712·26 enrolled

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Terminated·MMassachusetts General Hospital·Phase 2·NCT03292133·11 enrolled

Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00020709·840 enrolled

Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Completed·SSwiss Cancer Institute·Phase 2·NCT00217698·63 enrolled

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Terminated· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1·NCT03599518·20 enrolled

Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

Withdrawn·BBarbara Ann Karmanos Cancer Institute·Phase 1/2·NCT00268255

Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients

Completed·BBetta Pharmaceuticals Co., Ltd.·Phase 3·NCT01040780·399 enrolled

Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00409006·70 enrolled

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Unknown status·TThe First Affiliated Hospital of Soochow University·N/A·NCT03766490·66 enrolled

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

Active, not recruiting·BBeta Pharma Shanghai·Phase 3·NCT03866499·369 enrolled

High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations

Completed·—·Phase 1·NCT00372515·7 enrolled

A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Unknown status·NNanjing Sanhome Pharmaceutical, Co., Ltd.·Phase 3·NCT04239833·240 enrolled

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

Completed·AAVEO Pharmaceuticals, Inc.·Phase 1/2·NCT01039948·203 enrolled

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02088112·56 enrolled

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00062062·65 enrolled

Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·MMassachusetts General Hospital·Phase 2·NCT00411047·34 enrolled

ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Unknown status· AstraZeneca logo

AstraZeneca·Phase 3·NCT00006049

Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer

Unknown status·NNational Cancer Center, Korea·Phase 3·NCT00955695·242 enrolled

Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 1/2·NCT00098462

Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ?

Completed·TTaipei Veterans General Hospital, Taiwan··NCT02740894·100 enrolled

ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Unknown status· AstraZeneca logo

AstraZeneca·Phase 3·NCT00006048

A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01469000·195 enrolled

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

Unknown status·SSamsung Medical Center·Phase 2·NCT03399669·100 enrolled

Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00005806

Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer

Completed·YYonsei University·Phase 2·NCT01498562·160 enrolled

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Completed· Pfizer logo

Pfizer··NCT05834348·5,279 enrolled

Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer

Unknown status·GGuangdong Provincial People's Hospital·Phase 2·NCT00614809·45 enrolled

Breast Cancer12 trials

A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00234403·60 enrolled

The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer

Unknown status·UUnknown Sponsor·Phase 2·NCT01732276·50 enrolled

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00057941·148 enrolled

Show 9 more trials

Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer

Completed·—·Phase 2·NCT00080743·2 enrolled

Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00077025·174 enrolled

Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT00049062

Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00066339·44 enrolled

Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00319618·66 enrolled

Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00066378·71 enrolled

Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

Completed·—·Phase 1/2·NCT00086957·31 enrolled

ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00247481·77 enrolled

Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00024154·132 enrolled

Gefitinib10 trials

First Line Gefitinib by FDG-PET Metabolic Response

Unknown status·—·Phase 2·NCT01510990·60 enrolled

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

Unknown status·SSun Yat-sen University·Phase 2·NCT01955421·224 enrolled

Bioequivalence Study of Gefitinib Tablets Under Fed Conditions

Completed·HHunan Kelun Pharmaceutical Co., Ltd.·Phase 1·NCT03050177·38 enrolled

Show 7 more trials

Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone

Completed·SSpanish Lung Cancer Group·Phase 1/2·NCT01513174·186 enrolled

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00588445·65 enrolled

Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib

Terminated·PPapworth Hospital NHS Foundation Trust·Phase 2·NCT01405846·32 enrolled

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

Completed·HHutchison Medipharma Limited·Phase 1·NCT02374645·64 enrolled

Gefitinib Combined With Thalidomide to Treat NSCLC

Unknown status·BBai Jun·Phase 2/3·NCT02387086·380 enrolled

Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients

Completed·GGachon University Gil Medical Center·Phase 2·NCT01783834·95 enrolled

Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC

Unknown status·GGachon University Gil Medical Center·Phase 2·NCT00319800·50 enrolled

Lung Cancer8 trials

Hydroxychloroquine and Gefitinib to Treat Lung Cancer

Unknown status·NNational University Hospital, Singapore·Phase 1/2·NCT00809237·71 enrolled

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02179671·32 enrolled

Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer

Unknown status·QQilu Hospital of Shandong University·Phase 4·NCT02031601·250 enrolled

Show 5 more trials

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Unknown status·SSun Yat-sen University·Phase 3·NCT02824458·246 enrolled

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT03944772·247 enrolled

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Active, not recruiting·—·Phase 1/2·NCT03122717·48 enrolled

PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery

Completed·NNational Cancer Centre, Singapore·Phase 2·NCT02804776·15 enrolled

A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00255489·36 enrolled

Small Cell Lung Cancer6 trials

the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)

Unknown status·JJiangsu Famous Medical Technology Co., Ltd.·Phase 4·NCT03264794·100 enrolled

ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00252798·44 enrolled

Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

Suspended·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT00986284·102 enrolled

Show 3 more trials

A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01017874·236 enrolled

A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00298688·56 enrolled

Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer

Completed·GGuangdong Association of Clinical Trials·Phase 3·NCT01404260·219 enrolled

75 more indications

Prostate Cancer5 trials

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

Terminated·UUniversity of Nebraska·Phase 2·NCT00483561·26 enrolled

Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00241475·30 enrolled

ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00025116·40 enrolled

Show 2 more trials

Open Label Trial to Assess Iressa in Prostate Cancer Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00635856·100 enrolled

Trial of Iressa in Prostate Cancer Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00265070·80 enrolled

Advanced NSCLC5 trials

Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients

Terminated·AAmsterdam UMC, location VUmc·Phase 2·NCT02025218·21 enrolled

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Completed· Pfizer logo

Pfizer·Phase 3·NCT01774721·452 enrolled

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT01203917·1,060 enrolled

Show 2 more trials

Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01530334·61 enrolled

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Completed·CChinese Society of Lung Cancer·Phase 3·NCT01024413·256 enrolled

Adenocarcinoma4 trials

Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma

Unknown status·SShanghai University of Traditional Chinese Medicine·Phase 3·NCT02929693·198 enrolled

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00344773·46 enrolled

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01466660·319 enrolled

Show 1 more trial

Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma

Completed·SShanghai University of Traditional Chinese Medicine·Phase 3·NCT02889692·23 enrolled

EGFR Mutation4 trials

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT03267654·100 enrolled

Blood Detection of EGFR Mutation For Iressa Treatment

Unknown status·PPeking University Cancer Hospital & Institute·N/A·NCT02282267·188 enrolled

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance

Unknown status·CCaicun Zhou·Phase 2·NCT02930954·180 enrolled

Show 1 more trial

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

Unknown status· Sunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd.·Phase 1/2·NCT03758287·158 enrolled

Esophageal Cancer4 trials

Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer

Terminated·RRoswell Park Cancer Institute·Phase 1/2·NCT00093652

Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery

Terminated·UUniversity of California, San Francisco·Phase 1·NCT00290719·6 enrolled

Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery

Terminated·UUniversity of Rochester·Phase 2·NCT00258297·30 enrolled

Show 1 more trial

Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00100945·70 enrolled

Glioblastoma Multiforme4 trials

Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00014170·92 enrolled

ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse

Completed·—·Phase 2·NCT00016991

Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00052208·158 enrolled

Show 1 more trial

A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00238797·36 enrolled

Lung Adenocarcinoma4 trials

Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma

Unknown status·TTang-Du Hospital·Phase 3·NCT02518802·220 enrolled

First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker

Completed·NNational Cancer Center, Korea·Phase 3·NCT00455936·315 enrolled

Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature

Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT00198380·90 enrolled

Show 1 more trial

Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers

Unknown status·NNational Cancer Center, Korea·Phase 2·NCT01502202·162 enrolled

Treatment3 trials

Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg

Completed·SSun Yat-sen University·Phase 2·NCT01017679·96 enrolled

Third-line Treatment of Gefitinib in NSCLC Patients

Completed·GGuangdong Association of Clinical Trials·Phase 2·NCT01933347·46 enrolled

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT03040973·29 enrolled

Phase II3 trials

Iressa 2nd Line Phase III Study in Japan

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00252707·484 enrolled

Phase II Iressa + Irradiation Followed by Chemo in NSCLC

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00333294·50 enrolled

Phase II Iressa & Carbo/Gem in NSCLC

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00264498·38 enrolled

Colorectal Cancer3 trials

IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT00242788·40 enrolled

Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00052585·50 enrolled

Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer

Completed·SStanford University·Phase 2·NCT00025142

Metastatic Colorectal Cancer3 trials

Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00025350

Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer

Terminated·RRoswell Park Cancer Institute·Phase 1/2·NCT00087334·10 enrolled

ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00026364·22 enrolled

Head and Neck Cancer3 trials

Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00033449·30 enrolled

Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 3·NCT00088907·270 enrolled

Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193284·50 enrolled

NSCLC3 trials

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Active, not recruiting· Novartis logo

Novartis·Phase 1·NCT03333343·105 enrolled

SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00608868·156 enrolled

Iressa v BSC (Best Supportive Care) in First Line NSCLC

Completed· AstraZeneca logo

AstraZeneca·Phase 2/3·NCT00259064·216 enrolled

Adjuvant Treatment2 trials

A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

Unknown status·YYonsei University·Phase 3·NCT03381066·225 enrolled

Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation

Unknown status·GGuangdong Association of Clinical Trials·Phase 3·NCT01405079·222 enrolled

Metastatic Prostate Cancer2 trials

Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT00239291·42 enrolled

Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00085566·61 enrolled

Gastric Cancer2 trials

Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer

Terminated· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT00237900·34 enrolled

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Completed·SSamsung Medical Center·Phase 2·NCT03170180·66 enrolled

Radiotherapy2 trials

IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00242749·47 enrolled

Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·N/A·NCT03381430·50 enrolled

Growth2 trials

Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT01755923·60 enrolled

Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)

Unknown status·SShanghai Chest Hospital·Phase 2/3·NCT02338011·210 enrolled

Kidney Cancer2 trials

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

Terminated·CCalifornia Cancer Consortium·Phase 2·NCT00467077·21 enrolled

ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00014183

Chemotherapy2 trials

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

Terminated·SSichuan University·Phase 4·NCT02299765·61 enrolled

Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy

Unknown status·FFudan University·Phase 1·NCT00497250·32 enrolled

Skin Cancer2 trials

Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer

Unknown status·UUniversity of California, San Diego·Phase 1/2·NCT00423397·16 enrolled

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00126555·23 enrolled

Locally Advanced or Metastatic NSCLC2 trials

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT01982955·88 enrolled

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Active, not recruiting·JJiangsu Aosaikang Pharmaceutical Co., Ltd.·Phase 3·NCT04143607·337 enrolled

First-line Treatment2 trials

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Unknown status· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 3·NCT03849768·429 enrolled

Combination of Chemotherapy and Gefitinib as First-line Treatment

Completed·BBaohui Han·N/A·NCT02148380·121 enrolled

Bladder Cancer2 trials

BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

Terminated·NNCIC Clinical Trials Group·Phase 3·NCT00352079·41 enrolled

Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00041106·50 enrolled

Anlotinib2 trials

Phase I Study of the Combination of Anlotinib With Gefitinib

Unknown status·SSecond Affiliated Hospital of Nanchang University·N/A·NCT03602027·9 enrolled

Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC

Unknown status·SSun Yat-sen University·Phase 3·NCT04028778·310 enrolled

Patients With Advanced Solid Tumors2 trials

Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00084786

Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors

Completed·RRoswell Park Cancer Institute·Phase 1·NCT00084708·53 enrolled

Glioma2 trials

Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00027625

Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00042991·69 enrolled

Neoadjuvant2 trials

Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00188617·35 enrolled

Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00255463·185 enrolled

Pancreatic Cancer2 trials

IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT00234416·45 enrolled

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Active, not recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT06630325·30 enrolled

Head and Neck2 trials

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00206219·477 enrolled

The IRESSA Novel Head and Neck Chemotherapy Evaluation Study

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00255476·64 enrolled

Cushing's Disease1 trial

Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease

Unknown status·HHuashan Hospital·Phase 2·NCT02484755·6 enrolled

Fasting Conditions1 trial

Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions

Completed·HHunan Kelun Pharmaceutical Co., Ltd.·Phase 1·NCT03050164·38 enrolled

Colorectal Carcinoma1 trial

A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma

Completed· AstraZeneca logo

AstraZeneca·Phase 2/3·NCT00234429·74 enrolled

Renal Cell Carcinoma1 trial

Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma

Completed· Pfizer logo

Pfizer·Phase 1/2·NCT00113529·42 enrolled

Metformin1 trial

Combination of Metformin With Gefitinib to Treat NSCLC

Completed·—·Phase 2·NCT01864681·224 enrolled

Vinorelbine1 trial

Phase II Iressa Versus Vinorelbine (INVITE)

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00256711·192 enrolled

Fallopian Tube Cancer1 trial

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00317772·19 enrolled

Recurrent or Metastatic1 trial

Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00127829·66 enrolled

CNS Tumors1 trial

Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00025675·105 enrolled

Gemcitabine1 trial

Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00246974·125 enrolled

Leukemia1 trial

Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Completed·—·Phase 2·NCT00130702·18 enrolled

Safety and Efficacy1 trial

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Completed· Novartis logo

Novartis·Phase 2·NCT01610336·161 enrolled

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00040781·45 enrolled

Cervical Cancer1 trial

Gefitinib in Treating Patients With Cervical Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00049556

Gallbladder Carcinoma1 trial

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT02836847·152 enrolled

Surgical1 trial

Ph II Early BC Pre-Surgical Biologic Study

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00637026·65 enrolled

Central Nervous System1 trial

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases

Completed·AAlpha Biopharma (Jiangsu) Co., Ltd.·Phase 2/3·NCT03653546·492 enrolled

Hepatocellular Carcinoma1 trial

Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00071994·59 enrolled

Advanced Cancer1 trial

S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract

Completed·SSWOG Cancer Research Network·Phase 2·NCT00014144·31 enrolled

Head Neck Cancer1 trial

Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT00239304·40 enrolled

Ductal Carcinoma in Situ1 trial

Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast

Terminated·VVanderbilt-Ingram Cancer Center·Phase 2·NCT00082667·1 enrolled

Randomized1 trial

Randomized Gefitinib Trial

Completed·FFondazione Humanitas per la Ricerca·Phase 3·NCT00807066·1 enrolled

Radiation Therapy1 trial

Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases

Completed·SSwiss Cancer Institute·Phase 2·NCT00238251·59 enrolled

Metastatic1 trial

Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00229697·317 enrolled

Malignant Mesothelioma1 trial

Gefitinib in Treating Patients With Malignant Mesothelioma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00025207·40 enrolled

Efficacy and Safety1 trial

Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy

Completed·—·Phase 2·NCT01485809·36 enrolled

Metastatic NSCLC1 trial

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT02411448·545 enrolled

Metastatic Neuroendocrine Tumor1 trial

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00075439·90 enrolled

Clinical Trial1 trial

Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients

Unknown status·SSun Yat-sen University·Phase 3·NCT03203590·590 enrolled

Carboplatin1 trial

First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00322452·1,329 enrolled

Osimertinib1 trial

Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)

Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT02856893·156 enrolled

Primary Peritoneal Cancer1 trial

Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Completed·GGynecologic Oncology Group·Phase 2·NCT00023699

Head and Neck Carcinoma1 trial

Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00228488·60 enrolled

Thyroid Cancer1 trial

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

Completed·MMassachusetts General Hospital·Phase 2·NCT00095836·27 enrolled

Metastatic Head and Neck Cancer1 trial

Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00024089·60 enrolled

Real-world Study1 trial

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study

Unknown status·GGuangdong Association of Clinical Trials··NCT04575415·272 enrolled

Endometrial Cancer1 trial

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00027690·56 enrolled

Trial1 trial

Iressa Follow-up Trial

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00357734·14 enrolled

Non-squamous NSCLC1 trial

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Unknown status·HHenan Cancer Hospital·Phase 2·NCT03457337·200 enrolled

ESS1 trial

Iressa Versus Docetaxel (Taxotere)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00076388·1,440 enrolled

Survival1 trial

Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00242801·1,692 enrolled

Salivary Gland Cancer1 trial

Iressa Study in Patients With Salivary Gland Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00509002·37 enrolled

Osteosarcoma1 trial

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07477457·45 enrolled

Regulatory

FDA Approval Timeline[5]

May 5, 2003

IRESSA

NDA NDA021399

Jul 13, 2015

IRESSA

NDA NDA206995

Sources

References

[1]
ClinicalTrials.gov — 251 trial records for Gefitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Iressa drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Gefitinib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Gefitinib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA206995). U.S. Food & Drug Administration.
[6]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Epidermal Growth Factor Receptor Erbb1 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AstraZeneca

Iressa

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q3 2027

Q4 2027

Trials by Indication[1]

Non-Small Cell Lung Cancer37 trials

Breast Cancer12 trials

Gefitinib10 trials

Lung Cancer8 trials

Small Cell Lung Cancer6 trials

Prostate Cancer5 trials

Advanced NSCLC5 trials

Adenocarcinoma4 trials

EGFR Mutation4 trials

Esophageal Cancer4 trials

Glioblastoma Multiforme4 trials

Lung Adenocarcinoma4 trials

Treatment3 trials

Phase II3 trials

Colorectal Cancer3 trials

Metastatic Colorectal Cancer3 trials

Head and Neck Cancer3 trials

NSCLC3 trials

Adjuvant Treatment2 trials

Metastatic Prostate Cancer2 trials

Gastric Cancer2 trials

Radiotherapy2 trials

Growth2 trials

Kidney Cancer2 trials

Chemotherapy2 trials

Skin Cancer2 trials

Locally Advanced or Metastatic NSCLC2 trials

First-line Treatment2 trials

Bladder Cancer2 trials

Anlotinib2 trials

Patients With Advanced Solid Tumors2 trials

Glioma2 trials

Neoadjuvant2 trials

Pancreatic Cancer2 trials

Head and Neck2 trials

Cushing's Disease1 trial

Fasting Conditions1 trial

Colorectal Carcinoma1 trial

Renal Cell Carcinoma1 trial

Metformin1 trial

Vinorelbine1 trial

Fallopian Tube Cancer1 trial

Recurrent or Metastatic1 trial

CNS Tumors1 trial

Gemcitabine1 trial

Leukemia1 trial

Safety and Efficacy1 trial

Squamous Cell Carcinoma1 trial

Synovial Sarcoma1 trial

Refractory Solid Tumors1 trial

Cervical Cancer1 trial

Gallbladder Carcinoma1 trial

Surgical1 trial

Central Nervous System1 trial

Hepatocellular Carcinoma1 trial

Advanced Cancer1 trial

Head Neck Cancer1 trial

Ductal Carcinoma in Situ1 trial

Randomized1 trial

Radiation Therapy1 trial

Metastatic1 trial

Malignant Mesothelioma1 trial

Efficacy and Safety1 trial

Metastatic NSCLC1 trial

Metastatic Neuroendocrine Tumor1 trial

Clinical Trial1 trial

Carboplatin1 trial

Osimertinib1 trial

Primary Peritoneal Cancer1 trial

Head and Neck Carcinoma1 trial

Thyroid Cancer1 trial